Global Medical REIT (GMRE)
NYSE:GMRE
Advertisement

Global Medical REIT (GMRE) AI Stock Analysis

Compare
804 Followers

Top Page

GMRE

Global Medical REIT

(NYSE:GMRE)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
$33.00
▲(1.88% Upside)
Global Medical REIT's overall stock score is primarily impacted by financial performance challenges, including negative profitability and cash flow issues. While the earnings call provided some positive insights into debt management and NOI growth, the technical indicators suggest a bearish trend, and the valuation metrics highlight significant risks. The high dividend yield may appeal to some investors, but the underlying financial instability poses a considerable risk.
Positive Factors
Debt Maturity Management
Extending debt maturities improves financial stability and reduces refinancing risk, supporting long-term operational flexibility.
Same-Store NOI Growth
Consistent NOI growth reflects strong property performance and enhances revenue predictability, supporting sustainable income streams.
Strong Leasing and Occupancy
High occupancy rates indicate strong demand for properties, ensuring stable rental income and reducing vacancy risks.
Negative Factors
Profitability Challenges
Negative profit margins highlight operational inefficiencies, impacting the company's ability to generate sustainable profits.
Cash Flow Decline
Declining cash flow limits the company's ability to reinvest in growth opportunities and meet financial obligations.
Limited Acquisition Execution
High capital costs restrict acquisition capabilities, potentially hindering growth and portfolio diversification.

Global Medical REIT (GMRE) vs. SPDR S&P 500 ETF (SPY)

Global Medical REIT Business Overview & Revenue Model

Company DescriptionGlobal Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.
How the Company Makes MoneyGlobal Medical REIT generates revenue primarily through long-term leases with healthcare operators. The company acquires properties that are typically leased on a triple-net basis, meaning that tenants are responsible for property taxes, insurance, and maintenance costs, which minimizes the operating expenses for GMRE. This structure allows GMRE to earn rental income that is largely predictable and stable. Additionally, GMRE may benefit from property appreciation and increased rental rates over time as demand for healthcare services grows. Strategic partnerships with healthcare providers can also enhance its portfolio by acquiring high-quality properties that are well-positioned in the market, contributing to both occupancy rates and rental income.

Global Medical REIT Earnings Call Summary

Earnings Call Date:Nov 04, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Neutral
The earnings call demonstrated effective management of debt maturities and notable growth in same-store NOI and leasing activities. However, the company faces challenges with limited acquisition capabilities due to high capital costs, a high payout ratio, and tenant credit concerns. Overall, the positives slightly outweigh the negatives.
Q3-2025 Updates
Positive Updates
Debt Maturity Management
Successfully recasted the revolver to 2029 and extended the $350 million Term Loan A, breaking it into three distinct loans and extending the weighted average debt term by 3 years.
Same-Store NOI Growth
Achieved 2.7% same-store NOI growth, indicating improved property performance and consistent results.
Strong Leasing and Occupancy
Portfolio was 95.2% leased with expectations to trend towards 96% occupancy by year-end. Successful re-leasing of an 85,000 square foot facility in Beaumont, Texas.
Funds from Operations Growth
Delivered funds from operations of $14.5 million, growing 4% on a per share basis relative to the prior year.
Credit Facility Amendment
Amended credit facility to extend the term of revolver and Term Loan A, removing the 10 basis point SOFR credit spread from borrowings.
Negative Updates
Limited Acquisition Execution
Despite evaluating $11.5 billion in prospective transactions, execution on deals is limited due to current cost of capital.
High Payout Ratio
Funds available for distribution resulted in a payout ratio of 84% at the current annual dividend rate, indicating limited room for error.
Tenant Credit Challenges
Concerns over tenant credit watch list with previous issues like Steward and Prospect, though the list is reportedly shrinking.
Company Guidance
During the Global Medical REIT Third Quarter 2025 earnings call, the company provided guidance highlighting several key metrics and strategic initiatives. The company reported a 2.7% increase in same-store Net Operating Income (NOI) and announced efforts to extend debt maturities by recasting their revolver to 2029 and restructuring their $350 million Term Loan A into three separate loans. The company achieved funds from operations of $14.5 million or $1 per share, with adjusted funds from operations at $16.2 million or $1.12 per share, both growing 4% year-over-year. The payout ratio was reported at 84% based on a year-to-date funds available for distribution of $39.2 million. The portfolio was 95.2% leased with a weighted average lease term (WAULT) of over 5 years and embedded annual escalators of 2.1%. The company plans to maintain discipline in capital allocation, focusing on asset recycling as a primary funding source for new investments, given their cost of capital constraints. Looking forward, the management team is developing a strategic plan aimed at delivering exceptional shareholder returns through a combination of internal earnings growth, disciplined capital allocation, and opportunistic external growth.

Global Medical REIT Financial Statement Overview

Summary
Global Medical REIT faces profitability and cash flow challenges despite moderate revenue growth. The company has managed to reduce leverage, but negative net profit margins and declining cash flow metrics suggest operational inefficiencies and financial instability. Strategic improvements are needed to enhance profitability and cash flow generation.
Income Statement
45
Neutral
The income statement shows moderate revenue growth with a 4.51% increase in TTM. However, the net profit margin is negative at -1.29%, indicating profitability challenges. Gross profit margin has decreased significantly from previous years, suggesting increased cost pressures. EBIT and EBITDA margins have also declined, reflecting reduced operational efficiency.
Balance Sheet
55
Neutral
The balance sheet reveals a stable equity ratio, but the debt-to-equity ratio has improved to 1.50, indicating a reduction in leverage. Return on equity is negative, highlighting profitability issues. The company maintains a reasonable equity ratio, suggesting a balanced asset structure.
Cash Flow
40
Negative
Cash flow analysis shows a significant decline in free cash flow growth, with a negative growth rate of -135.51% in TTM. The operating cash flow to net income ratio is not calculable due to negative net income, and free cash flow to net income ratio is negative, indicating cash flow challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue147.99M138.41M140.93M137.17M115.80M93.52M
Gross Profit101.76M109.16M112.85M111.98M100.32M82.65M
EBITDA83.19M91.47M111.64M102.89M85.35M53.00M
Net Income2.50M6.63M20.61M19.14M17.62M-1.93M
Balance Sheet
Total Assets1.27B1.26B1.27B1.39B1.26B1.10B
Cash, Cash Equivalents and Short-Term Investments7.12M6.82M1.28M4.02M7.21M5.51M
Total Debt728.66M653.59M624.19M704.65M579.86M607.62M
Total Liabilities767.41M700.57M661.89M744.20M625.91M643.15M
Stockholders Equity485.29M534.13M583.58M632.98M622.78M444.81M
Cash Flow
Free Cash Flow18.63M-25.07M58.39M-79.66M-132.69M-184.27M
Operating Cash Flow72.50M70.05M68.44M76.54M68.97M34.52M
Investing Cash Flow-86.67M-45.94M67.62M-137.25M-194.66M-223.67M
Financing Cash Flow16.23M-21.89M-143.79M62.41M127.70M192.72M

Global Medical REIT Technical Analysis

Technical Analysis Sentiment
Negative
Last Price32.39
Price Trends
50DMA
33.08
Negative
100DMA
33.75
Negative
200DMA
34.80
Negative
Market Momentum
MACD
-0.03
Negative
RSI
51.10
Neutral
STOCH
81.14
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMRE, the sentiment is Negative. The current price of 32.39 is above the 20-day moving average (MA) of 31.77, below the 50-day MA of 33.08, and below the 200-day MA of 34.80, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 51.10 is Neutral, neither overbought nor oversold. The STOCH value of 81.14 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GMRE.

Global Medical REIT Risk Analysis

Global Medical REIT disclosed 67 risk factors in its most recent earnings report. Global Medical REIT reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Global Medical REIT Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$1.30B33.282.77%6.76%3.74%77.82%
69
Neutral
$158.10M19.4152.29%4.90%29.76%22.76%
69
Neutral
$548.98M30.5510.55%7.40%0.68%-1.34%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
62
Neutral
$421.38M-2.32%12.35%3.40%-240.85%
56
Neutral
$1.12B-18.84%0.86%4.10%8.96%
50
Neutral
$476.40M0.49%11.15%2.73%-131.16%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GMRE
Global Medical REIT
32.39
-6.92
-17.60%
DHC
Diversified Healthcare Trust
4.58
2.16
88.87%
CHCT
Community Healthcare
15.26
-1.36
-8.18%
UHT
Universal Health Realty Income
39.86
2.19
5.81%
STRW
Strawberry Fields REIT Inc
11.97
0.73
6.49%
SILA
Sila Realty Trust, Inc.
23.73
-0.36
-1.49%

Global Medical REIT Corporate Events

Global Medical REIT Reports Q3 2025 Financial Results
Nov 6, 2025

Global Medical REIT Inc. is a real estate investment trust specializing in acquiring and leasing healthcare facilities to physician groups and healthcare systems. In its third-quarter 2025 financial report, the company announced a net loss of $6.0 million, primarily due to a $6.3 million impairment charge on a facility in Aurora, IL, which was sold during the quarter. Despite this, the company reported a 4% year-over-year increase in both Funds from Operations (FFO) and Adjusted Funds from Operations (AFFO), with FFO at $14.5 million and AFFO at $16.2 million. Rental revenue rose by 8.4% to $37.0 million, driven by recent acquisitions. The company also completed a one-for-five reverse stock split and established a $50 million share repurchase program. Looking ahead, Global Medical REIT remains focused on optimizing its portfolio and maintaining high occupancy rates, with a 2025 AFFO guidance range of $4.50 to $4.60 per share.

Global Medical REIT Inc’s Earnings Call Highlights Balanced Outlook
Nov 6, 2025

Global Medical REIT Inc’s recent earnings call highlighted a cautiously optimistic sentiment, with effective management of debt maturities and notable growth in same-store NOI and leasing activities. Despite these positives, the company faces challenges such as limited acquisition capabilities due to high capital costs, a high payout ratio, and tenant credit concerns. Overall, the positives slightly outweigh the negatives, reflecting a balanced outlook for the company’s financial health.

Business Operations and StrategyPrivate Placements and Financing
Global Medical REIT Announces Amended Credit Facility
Positive
Oct 8, 2025

On October 8, 2025, Global Medical REIT Inc. announced a third amended and restated credit facility with JPMorgan Chase Bank, extending the maturity dates of its $400 million revolver and $350 million term loan, now divided into three tranches maturing between 2029 and 2031. The amendment removes a previous credit spread adjustment and maintains the pricing grid and $500 million accordion feature, resulting in an increased weighted average debt term from 1.3 years to 4.4 years, potentially enhancing the company’s financial stability and operational flexibility.

The most recent analyst rating on (GMRE) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.

Stock Split
Global Medical REIT Announces Reverse Stock Split
Neutral
Sep 19, 2025

On September 18, 2025, Global Medical REIT Inc. implemented a one-for-five reverse stock split, reducing its authorized common stock from 500 million to 100 million shares. This adjustment, effective September 19, 2025, did not affect the company’s preferred stock or shareholders’ ownership percentages, except for minor changes due to fractional shares being settled in cash. The common stock will trade on a split-adjusted basis on the NYSE from September 22, 2025.

The most recent analyst rating on (GMRE) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the GMRE Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 12, 2025